Selective muscarinic receptor agonists and antagonists

Pharmacology and Toxicology

Volumn 78, Issue 2, 1996, Pages 59-68

  Eglen, Richard M ^a   Watson, Nikki ^b  

^a ROCHE BIOSCIENCE   (United States)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; 2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE TARTRATE; 3 (2 DIETHYLAMINO 2 METHYLPROPYLAMINO) 6 PHENYL 5 PROPYLPYRIDAZINE; 3 (6 CHLORO 2 PYRAZINYL)QUINUCLIDINE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; 8 [3 (4 DIETHYLCARBAMOYL 1 PIPERAZINYL)PROPYL] 1,3,7 TRIMETHYLXANTHINE; ALVAMELINE; CEVIMELINE; CYCLIC AMP; DIACYLGLYCEROL; HIMBACINE; INOSITOL 1,4,5 TRISPHOSPHATE; METHOCTRAMINE; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OTENZEPAD; PARA FLUOROHEXAHYDROSILADIFENIDOL; PIRENZEPINE; RECEPTOR SUBTYPE; SABCOMELINE; TALSACLIDINE; TELENZEPINE; THIOPILOCARPINE; TRIPITRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG INDICATION; DRUG SELECTIVITY; HUMAN; MOLECULAR CLONING; NERVOUS SYSTEM; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE;

ANIMALIA;

EID: 0030052086     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00181.x     Document Type: Review

References (101)

1. Adamus, W. S., J. P. Leonard & W. Troger: Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. Life Sci 1995, 56, 883-890.
2. 3H-acetylcholine secretion in the guinea-pig urinary bladder in vitro. J. Pharmacol. Exp. Therap. 1995, 274, 458-468.
3. Andersson, K.-E.: Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol. Rev. 1993, 45, 253-308.
4. Barnes, P. J.: Muscarinic receptor subtypes in airways. Life Sci. 1993, 52, 521-527.
5. Bartus, R. T., R. L. Dean, III, B. Beer & A. S. Lippa: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-417.
6. Black, J. W. & N. P. Shankley: Pharmacological analysis of the muscarinic receptors coupled to oxyntic cell secretion in the mouse stomach. Brit. J. Pharmacol. 1985, 86, 601-607.
7. 4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn-Schmiedeberg's Arch. Pharmacol. 1992, 345, 611-618.
8. Brann, M. R., J. Ellis, H. Jorgensen, D. Hill-Eubanks & S. V. Jones: Muscarinic acetylcholine receptor subtypes: localization and structure/function. Prog. Brain Res. 1993, 98, 121-127.
9. Burgen, A. S. V.: The background of the muscarinic system. Life Sci 1995, 56, 801-806.
10. q. FEBS Letts 1995, 363, 261-263.
11. Carmine, A. A. & R. N. Brogden: Pirenzepine, A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs 1985 30, 85-126.
12. Carter, J. P., L. Noronha-Blob, V. H. Audia, A. C. Dupont, D. W. McPherson, K. J. Natalie, W. J. Rzeszotarski, C. J. Spagnuolo, P. P. Waid & C. Kaiser: Analogues of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds. J. Med. Chem. 1991, 34, 3065-3074.
13. Caulfield, M. D.: Muscarinic receptors characterization, coupling and function. Pharmacol. Therap. 1993, 58, 319-379.
14. 2 receptors. Brit. J. Pharmacol. 1995, 114, 1507-1517.
15. Dale, H. H.: The action of certain esters and ethers of choline and their relation to muscarinc. J. Pharmacol. Exp. Therap. 1914, 6, 147-190.
16. Darroch, S. & F. Mitchelson: Characterization of a novel muscarine receptor in avian smooth muscle. Life Sci. 1995, 56, abstract 78.
17. Doods, H. N.: Selective muscarinic antagonists as bronchodilators. Drug News and Perspectives 1992, 5, 345-352.
18. 2 antagonists: novel structures and pharmacology. Life Sci. 1993a, 52, 497-503.
19. Doods, H. N., K. D. Willim, H. W. G. M. Boddeke & M. Entzeroth: Characterization of muscarinic receptors in guinea-pig uterus. Eur. J. Pharmacol. 1993b, 250, 223-230.
20. Durant, P. A. C., N. P. Shankley, N. J. Welsh & J. W. Black: Pharmacological analysis of agonist-antagonist interactions at acetylcholine muscarinic receptors in a new urinary bladder assay. Brit. J. Pharmacol. 1991, 104, 145-150.
21. Dörje, F., J. Wess, G. Umbrecht, R. Tacke, E. Mutschler & M. R. Brann: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Therap. 1991, 256, 727-733.
22. Eglen, R. M., A. D. Michel, B. A. Kenny & R. L. Whiting: Muscarinic activity of McN-A-343 and its value in muscarinic receptor classification. Brit. J. Pharmacol. 1987, 90, 693-700.
23. Eglen, R. M., A. D. Michel & R. L. Whiting: Characterization of the muscarinic receptor subtype mediating contractions of the guinea-pig uterus. Brit. J. Pharmacol. 1989, 96, 497-499.
24. Eglen, R. M. & R. L. Whiting: Heterogeneity of vascular muscarinic receptors. J. Auton. Pharmacol. 1990, 19, 233-245.
25. Eglen, R. M., Cornett, C. M. & R. L. Whiting: Interaction of pFHHSID at tracheal muscarinic receptors in vitro. Naunyn-Schmiedberg's Arch. Pharmacol. 1990, 342, 394-399.
26. Eglen, R. M., G. C. Harris, M. Taylor, J. R. Pfister & R. L. Whiting: Characterization of the muscarinic receptor mediating release of epithelial derived relaxant factor (EpDRF) in vitro. Naunyn-Schmiedeberg's Arch Pharmacol. 1992, 344, 29-35.
27. Eglen, R. M., H. Reddy & N. Watson: Selective inactivation of muscarinic receptor subtypes. Int. J. Biochem. 1994a, 26, 1357-1368.
28. Eglen, R. M., H. Reddy, N. Watson & R. A. J. Challiss: Muscarinic receptor subtypes in smooth muscle. Trends in Pharmacol. Sci. 1994b 15, 114-119.
29. Eglen, R. M., H. Reddy, E. Stefanich & N. Watson: The interaction of zamifenacin at muscarinic receptor subtypes in vitro. Can. J. Physiol. Pharmacol. 1994c, 72, 376.
30. 2 muscarinic receptors in the guinea-pig ileum. Life Sci. 1995, 56, 965-971.
31. 2 adrenoceptors. Brit. J. Pharmacol. 1995, in press.
32. Enz, A., H. Boddeke, A. Sauter, M. Rudin & G. Shapiro: SDZ ENS 163, a novel pilocarpine-like drug: pharmacological in vitro and in vivo profile. Life Sci. 1993, 52, 513-520.
33. 2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle. J. Pharmacol. Exp. Therap, 1992, 262, 119-126.
34. Flynn, D. D., G. Ferrari-DiLeo, D. C. Mash & A. I. Levey: Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 1995, 64, 1888-1891.
35. Ford, A. P. D. W., W. B. Levine, G. S. Baxter, G. C. Harris, R. M. Eglen & R. L. Whiting: Pharmacological, biochemical and molecular characterization of muscarinic receptors in the guinea-pig, ileum: a multidisciplinary approach. Mol. Neuropharmacol. 1991, 1, 117-127.
36. Freedman, S. B., E. A. Harley, S. Patel, N. R. newberry, M. J. Gilbert, A. T. McKnight, J. K. Tang, J. J. Maguire, N. T. Mudunkotuwa, R. Baker, L. J. Street, A. M. Maclleod, J. Saunders & L. L. Iversen: A novel series of non-quaternary oxadiazoles acting as full agonists at muscarinic receptors. Brit. J. Pharmacol. 1990, 101, 575-580.
37. Freedman, S. B., G. R. Dawson, L. L. Iversen, R. Baker & R. J. Hargreaves: The design of novel partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side effect profile in vivo. Life Sci. 1993, 52, 489-495.
38. Fuder, H. & E. Muscholl: Heteroreceptor-mediated modulation of noradrenaline and acetylcholine release from peripheral nerves. Revs. Physiol. Biochem. Pharmacol. 1995, 126, 265-412.
39. Fukuda, K., T. Kubo, A. Maeda, I. Akiba, H. Bujo, J. Nakai, M. Mishina, Higashida, E. Neher, A. Marty & S. Numa: Selective effector coupling of muscarinic acetylcholine receptor subtypes. Trends Pharmacol. Sci. 1989, Suppl. IV, 4-10.
40. Grimm, U., H. Fuder, U. Moser, H. G. Bumert, E. Mutschler & G. Lambrecht. Characterization of the prejunctional muscarinic receptors mediating inhibition of evoked release of endogenous noradrcnaline in rabbit isolated vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol. 1994a, 349, 1-10.
41. Grimm, U., U. Moser, E. Mutschler & G. Lambrecht: Muscarinic receptors: focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie 1994b, 49, 711-726.
42. Gross, N. J. & M. S. Skorodin: Anticholinergic antimuscarinic bronchodilators. Amer. Rev. Respir. Dis. 1984, 129, 856-870.
43. Guo, Z. D., K. Kameyama, A. Rinken & T. Haga: Ligand binding properties of muscarinic acetyleholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J. Pharmacol. Exp. Therap. 1995, 274, 378-384.
44. 3H]Ba 679 Br, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994, 45, 899-907.
45. 3 receptor stimulation in guinea-pig coronary artery. Brit. J. Pharmacol. 1995, 115, 717-722.
46. Hirschowitz, B. I., D. Keeling, M. Lewin, S. Okabe, M. Parsons, K. Sewing, B. Wallmark & G. Sachs: Pharmacological aspects of acid secretion. Dig. Dis. & Sci. 1995, 40, 3S-23S.
47. Hosey, M. M.: Diversity of structure, signaling and regulation within the family of muscarinic cholinergic receptors. FASEB J. 1992, 6, 845-852.
48. Houghton, L. A., J. Rogers, P. J. Whorwell, F. C. Campbell, A. Raimundo & J. Goka: Zamifenacin (UK 76-654) reduces meal-stimulated colonic motor activity in patients with irritable bowel syndrome (IBS). Gastroenterol. 1993, 104, A523.
49. Hua, X. Y., S. M. Back & T. L. Yaksh: Characterization of muscarinic receptors involved in tracheal CGRP release. Neuroreport 1994, 5, 2133-2136.
50. Hulme, E. C., N. J. M. Birdsall & N. J. Buckley: Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 633-673.
51. 4 receptors. FEBS Lett. 1994, 352, 91-94.
52. 3-muscarinic acetyleholine receptors in vitro. Mol. Pharmacol. 1990, 38, 836-840.
53. Kaiser, C. C. J. Spagnuolo, T. C. Adams, V. H. Audia, A. C. Dupont, H. Hatoum, V. C. Lowe, J. C. Prosser, B. L. Sturm & L. Noronha-Blob: Synthesis and antimuscarinic properties of some substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones. J. Med. Chem. 1992, 35, 4415-4424.
54. Kaiser, C., V. H. Audia, J. P. Carter, D. W. McPherson, P. P. Waid, V. C. Lowe & L. Noronha-Blob: 1-cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and related compounds. J. Med. Chem. 1993, 36, 610-616.
55. Kenakin, T. P., R. A. Bond & T. I. Bonner: Definition of pharmacological receptors. Pharmacol. Rev. 1992, 44, 351-362.
56. Kilbinger, H., R. S. von Bardeleben, H. Siefken & D. Wolf: Prejunctional muscarinic receptors regulating neurotransmitter release in airways. Life Sci. 1995, 56, 981-987.
57. 2β-selective muscarinic antagonist. Eur. J. Pharmacol. 1988, 152, 193-194.
58. 4 binding sites in rabbit lung, chicken heart and NG 108-15 cells. Mol. Pharmacol. 1990, 38, 805-815.
59. 1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993, 52, 441-448.
60. Lulich, K. M., J. W. Paterson & R. G. Goldie: Ipratropium, sodium chromoglycate and antihistamines. Med. J. Aust. 1995, 162, 157-159.
61. Maeda, A., T. Kubo, M. Mishina & S. Numa: Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes. FEBS Letts. 1988, 239, 339-442.
62. Maesen, F. P. V., J. J. Smeets, M. A. L. Costongs, P. J. G. Cornelissen & F. D. M. Wald: Ba 679 BR, a new long acting antimuscarinic bronchodilator: a pilot dose escalation study in COPD. Eur. Respir. J. 1993, 6, 1031-1036.
63. Maggio, R., P. Barbier, M. L. Bolognesi, A. Minarini, D. Tedeschi & C. Melchiorre: Binding profile of the selective muscarine receptor antagonist tripitramine. Eur. J. Pharmacol. 1994, 268, 459-462.
64. 2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental denervation. Science 1985, 228, 1115-1117.
65. McIntyre, P. & P. Quinn: Characterisation and comparison of muscarinic receptors in the dog ciliary muscle with ileum. Brit. J. Pharmacol. 1995, 115, 139P.
66. McRitchie, B., P. A. Merner & M. G. Dodd: In vivo selectivity of the novel muscarinic antagonist, zamifenacin, in the conscious dog. Brit. J. Pharmacol. 1993, 109, 38P.
67. 2 muscarinic receptor antagonists. J. Med. Chem. 1993, 36, 3734-3737.
68. Moltzen, E. K. & Bjornholm: Medicinal chemistry of muscarinic agonists: developments since 1990. Drugs of the Future 1995, 20, 37-54.
69. Morley, J.: Parasympatholytics in asthma. Pulmon. Pharmacol. 1974, 7, 159-168.
70. Nagtegaal, J. E., J.-W. J. Lammers, J. F. Rodrigues de Miranda & F. W. J. Gribnau: The search for pre-junctional inhibitory muscarinic receptors in human bronchus. Arch. Int. Pharmacodyn. 1993, 322, 91-104.
71. Oyasu, H., T. Yamamoto, N. Sato, R. Ozaki, T. Mukai, T. Ozaki, T. Nishii, H. Sato, T. Fujisawa, Z. Tozuka, Y. Koibuchi, T. Honbo, K. Esumi, M. Ohtsuka & K. Shimomura: Urinary bladder selective action of the new antimuscarinic compound vamicamide. Arzneimittelforsch./Drug Res. 1994, 44, 1242-1249.
72. Pennefather, J. N., T. A. Gillman & F. Mitchelson: Muscarinic receptors in rat uterus. Eur. J. Pharmacol. 1994, 262, 297-300.
73. 3 antagonist in vivo. Brit. J. Pharmacol. 1993, 109, 37P.
74. Quirion, R., A. Wilson, W. Rowe, I. Aubert, J. Richard, H. Doods, A. Parent, N. White & M. J. Meaney: Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory impaired rats. J. Neurosci. 1995, 15, 1455-1462.
75. 2 receptors and β-adrenoceptor subtypes in guinea-pig isolated ileum. Brit. J. Pharmacol. 1995, 114, 49-56.
76. Richards, M. H.: Pharmacology and second messenger interactions of cloned muscarinic receptors. Biochim. Pharmacol. 1991, 42, 1645-1653.
77. Richards, M. H. & P. L. M. van Giersbergen: Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Brit. J. Pharmacol. 1995, 114, 1241-1249.
78. Roffel, A. F., J. J. Hamstra, C. R. S. Elzinga & J. Zaagsma: Selectivity profile of some recent muscarinic antagonists in bovine and guinea-pig trachea and heart. Arch. Int. Pharmacodyn. 1994, 328, 82-92.
79. 2 receptors in functional antagonism in bovine trachea. Brit. J. Pharmacol. 1995, 115, 665-671.
80. Saunders, P. A., C. J. Hough, F. Fukamauchi, D.-M. Chuang: Characterization of muscarinic receptor antagonist binding of intact cerebellar granule cells. Can. J. Physiol. Pharmacol. 1994, 72, 379, abstract no. P19.9.42.
81. Schulte, B., C. Volz-Zang, E. Mutschler, C. Horne, D. Palm, A. Wellstein & H. F. Pitschner: AF-DX 116, a cardioselective muscarinic antagonist in humans: pharmacodynamic and pharmacokinetic properties. Clin. Pharmacol. Therap. 1991, 50, 372-378.
82. Schwartz, R. D., R. E. Davis, J. C. Jean, C. J. Spencer, H. Tecle & A. J. Thomas: Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 1993, 52, 465-472.
83. Sedman, A. J., H. Bockbrader & R. D. Schwarz: Preclinical and Phase I clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci. 1995, 56, 877-882.
84. 1 receptors. J. Pharmacol. Exp. Therap. 1994, 269, 271-281.
85. Starke, K., M. Gothert & H. Kilbinger: Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 1989, 69, 864-989.
86. Taira, N.: The autonomic pharmacology of the bladder. Annu. Rev. Pharmacol. 1972, 12, 197-208.
87. 2 muscarinic receptor in smooth muscle of guinea-pig ileum. Mol. Pharmacol. 1993, 44, 102-110.
88. 3-mediated contractions and phosphoinositide hydrolysis. J. Pharmacol. Exp. Therap. 1994, 271, 1042-1050.
89. Tucek S. & J. Proska: Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 1995, 16, 205-212.
90. Wallis, R. M., D. Alker, R. A. Burgess, P. E. Cross, D. T. Newgreen & P. Quinn: Zamifenacin: A novel gut selective muscarinic receptor antagonist. Brit. J. Pharmacol. 1993, 109, 36P.
91. 3 receptor antagonists. Life Sci. 1995, 56, 861-868.
92. 3 antagonist. Pharmacol. Res. 1995, 31, (suppl.), 54.
93. 3 receptor stimulation and antagonism on responses to isoprenaline in guinea-pig isolated trachea in vitro. Brit. J. Pharmacol. 1994, 112, 179-187.
94. Watson, N., H. R. Reddy & R. M. Eglen: Characterization of the muscarinic receptor subtype mediating contraction of canine saphenous vein. J. Auton. Pharmacol. 1995a, in press.
95. 3 receptors in guinea-pig isolated trachea: effects of selective muscarinic receptor alkylation. Eur. J. Pharmacol. 1995b, 278, 195-201.
96. Watson, N., H. Reddy, E. Stefanich & R. M. Eglen: Characterization of the interaction of zamifenacin at muscarinic receptors in vitro. Eur. J. Pharmacol. 1995c, in press.
97. Watson, N., H. Magnusson & K. F. Rabe: Antagonism of β adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol. Eur. J. Pharmacol. 1995d, 175, 307-310.
98. Wess, J.: Mutational analysis of muscarinic acetylcholine receptors: structural basis of ligand/receptor G protein interactions. Life Sci. 1993, 53, 1447-1463.
99. White, M. V.: Muscarinic receptors in human airways. J. All. Clin. Immunol. 1995, 95, 1065-1068.
100. Whitehouse, P. J., D. L. Price, R. G. Struble, A. E. Clark, J. T. Coyle & M. R. DeLong: Alzheirner's disease and senile dementia; loss of neurons in the basal forebrain. Science 1982, 215, 1237-1239.
101. 4 agonist. Eur. J. Pharmacol. 1994, 269, R1-R2.